Episode #190: August 2022 Research Review
Barbell Medicine Podcast
00:00
Obesity and GLP1 Receptor Agonists
These are medicines that we're having increasing experience with, both in the context of diabetes where they were originally studied and approved and more recently obesity as well. So it falls into a class called GLP1 receptor agonist or glucagon like peptide one receptor agonists. And this is basically hitting a receptor that is targeted by hormones that are made in our gut already. They impact the rate that our stomach empties and kind of moves food along in the GI tract. It can increase the release of insulin to handle the effects of the meal as it is digested and absorbed. Then I think most interestingly and most importantly, it has some effects in the brain as it relates to appetite and
Transcript
Play full episode
